Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer.

MLA

Zanker, Damien J., et al. “Intratumoral Administration of the Toll‐like Receptor 7/8 Agonist 3M‐052 Enhances Interferon‐driven Tumor Immunogenicity and Suppresses Metastatic Spread in Preclinical Triple‐negative Breast Cancer.” Clinical & Translational Immunology, vol. 9, no. 9, Sept. 2020, pp. 1–20. EBSCOhost, https://doi.org/10.1002/cti2.1177.

APA

Zanker, D. J., Spurling, A. J., Brockwell, N. K., Owen, K. L., Zakhour, J. M., Robinson, T., Duivenvoorden, H. M., Hertzog, P. J., Mullins, S. R., Wilkinson, R. W., & Parker, B. S. (2020). Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer. Clinical & Translational Immunology, 9(9), 1–20. https://doi.org/10.1002/cti2.1177

Chicago

Zanker, Damien J, Alex J Spurling, Natasha K Brockwell, Katie L Owen, Jasmine M Zakhour, Tina Robinson, Hendrika M Duivenvoorden, et al. 2020. “Intratumoral Administration of the Toll‐like Receptor 7/8 Agonist 3M‐052 Enhances Interferon‐driven Tumor Immunogenicity and Suppresses Metastatic Spread in Preclinical Triple‐negative Breast Cancer.” Clinical & Translational Immunology 9 (9): 1–20. doi:10.1002/cti2.1177.